B-Cell Epitope Discovery and Mechanisms of Antibody Protection: Genetic and Structural Basis for Influenza Neutralization

该合同支持鉴定源自流感血凝素的人B细胞表位，以及了解抗体介导的保护性免疫的基础研究，以及在适用时了解抗体反应的病理后果。重要性包括1）表位鉴定; 2）表位验证，其必须包括使用人样品的体外评价; 3）向免疫表位数据库和分析资源提交表位数据、计算机软件和结构数据;以及4）研究以帮助理解与新鉴定的表位相关的抗体引起的保护或发病机制。该合同的目标是全面绘制与神经氨酸酶蛋白结合的人类保护性抗体的表位，以及流感血凝素的广泛保护性位点。其目的是确定保护性抗原和表位，长期目标是将数据转化为用于监测实验疫苗研究中的表位特异性反应，基于结构的表位疫苗的合理设计，以及使用分离的人单克隆抗体（mAb）作为开发工具，用于开发未来作为人类预防和治疗分子。

This contract supports the identification of human B cell epitopes derived from influenza hemagglutinin, coupled with basic studies to understand protective immunity mediated by antibodies and, when applicable, pathological consequences of antibody responses. Milestones include 1) epitope identification; 2) epitope validation that must include in vitro evaluation using human samples; 3) submission of epitope data, computer software, and structural data to the Immune Epitope Database and Analysis Resource; and 4) studies to help understand the mechanisms of protection or pathogenesis elicited by antibodies associated with the newly identified epitopes. The goal of this contract is to comprehensively map the epitopes of human protective antibodies that bind to the neuraminidase protein and to broadly protective sites of influenza hemagglutinin. The purpose is to identify protective antigens and epitopes, with the long-term goal of translating the data for monitoring epitope-specific responses in experimental vaccine studies, rational design of structure-based epitope vaccines, and use of isolated human monoclonal antibodies (mAb) isolated as developmental tools for development future as prophylactic and therapeutic molecules in humans.